BEXLUTRY Drug Patent Profile
Which patents cover Bexlutry, and what generic alternatives are available?
Bexlutry is a drug marketed by Curium and is included in one NDA.
The generic ingredient in BEXLUTRY is lutetium lu-177 dotatate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the lutetium lu-177 dotatate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BEXLUTRY?
- What are the global sales for BEXLUTRY?
- What is Average Wholesale Price for BEXLUTRY?
Summary for BEXLUTRY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in BEXLUTRY? | BEXLUTRY excipients list |
| DailyMed Link: | BEXLUTRY at DailyMed |
US Patents and Regulatory Information for BEXLUTRY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Curium | BEXLUTRY | lutetium lu-177 dotatate | SOLUTION;INTRAVENOUS | 218525-001 | Sep 14, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
